Advertisement

Therapeutische Manipulation der Abstoßungsreaktion

  • Rudolf Peter Wüthrich

Zusammenfassung

Viele immunosuppressive Substanzen und Methoden sind seit den frühen sechziger Jahren entwickelt und in der klinischen Transplantationsmedizin angewendet worden (1). In diesem Kapitel soll ein Überblick über die geläufigsten Immunosuppressiva und deren Wirkungsmechanismus gegeben werden. Die pharmakologischen Aspekte und die therapeutische Anwendung werden in späteren Kapiteln erläutert.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Amend WJC, Suthanthiran M, Gamberoglio JG (1986) Immunosuppression following renal transplantation. In: Garvoy MR, Guttmann RD (eds) Renal transplantation, chap 4, Churchill-Livingstone, New York, pp 73–92Google Scholar
  2. 2.
    Amemiya H, Suzuki S, Ota K, Takahashi K, Sonoda T, Ishibashi M, Omoto R, Koyama I, Dohi K, Fukuda Y, Fukao K (1990) A novel rescue drug, 15-deoxysperagualin Transplantation 49: 337Google Scholar
  3. 3.
    Caine RY et al. (1989) Rapamycin for immunosuppression in organ allografting. Lancet 2: 227Google Scholar
  4. 4.
    Carpenter CB et al. (1989) Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation. Am J Kidney Dis 14(5)[suppl 2]: 54Google Scholar
  5. 5.
    Chan GLC, Canafax DM, Johnson CA (1987) The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 7 (5): 165PubMedGoogle Scholar
  6. 6.
    Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, Bach JF (1990) In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49: 697PubMedCrossRefGoogle Scholar
  7. 7.
    Dupont E, Wybran J, Toussaint C (1984) Glucocorticosteroids and organ transplantation. Transplantation 37: 4CrossRefGoogle Scholar
  8. 8.
    Elliott JF, Lin Y, Mizel SB, Bleackley RC, Harnish DG, Paetkau V (1984) Induction of interleukin-2 messenger RNA inhibited by cyclosporin A. Science 226: 1439PubMedCrossRefGoogle Scholar
  9. 9.
    Kahan BD (1989) Cyclosporine. N Engl J Med 321: 1725CrossRefGoogle Scholar
  10. 10.
    Kirkman RL, Araujo JL, Busch GJ, Carpenter CB, Milford EL, Reinherz EL, Schloss-man SF, Strom TB, Tilney NL (1983) Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. Transplantation 36: 620PubMedCrossRefGoogle Scholar
  11. 11.
    Mathieson PW, Cobbold SP, Hale G, Clark MR, Oliveira DBG, Lockwood CM, Waldmann H (1990) Monoclonal antibody therapy in systemic vasculitis. N Engl J Med 323: 250PubMedCrossRefGoogle Scholar
  12. 12.
    Moran M et al. (1990) Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal transplant recipients treated with cyclosporine and prednisone. N Engl J Med 322: 1183PubMedCrossRefGoogle Scholar
  13. 13.
    Nelson AM, Conn DL (1980) Glucocorticoids in rheumatic disease. Mayo Clin Proc 55: 758PubMedGoogle Scholar
  14. 14.
    Nelson PW (1984) Cyclosporine. Surg Gynecol Obstet 159: 297Google Scholar
  15. 15.
    Rosen MK, Standaert RF, Galat A, Nakatsuka M, Schreiber SL (1990) Inhibition of FKBP rotamase activity by immunosuppressant FK 506: twisted amide surrogate. Science 248: 863PubMedCrossRefGoogle Scholar
  16. 16.
    Shevach EM (1985) The effects of cyclosporin A on the immune system. Annu Rev Immunol 3: 397PubMedCrossRefGoogle Scholar
  17. 17.
    Soulillou JP, Cantarovich D, Le Mauff B, Giral M, Robillard N, Hourmant M, Hirn M, Jacques Y (1990) Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 322: 1175PubMedCrossRefGoogle Scholar
  18. 18.
    Starzl TE, Fung J, Jordan M, Shapiro R, Tsakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M, Todo S (1990) Kidney transplantation under FK 506. JAMA 264: 63PubMedCrossRefGoogle Scholar
  19. 19.
    Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A (1989) FK 506 for liver, kidney, and pancreas transplantation. Lancet 2: 1000PubMedCrossRefGoogle Scholar
  20. 20.
    Strom TB (1984) Immunosuppressive agents in renal transplantation. Kidney Int 26: 353PubMedCrossRefGoogle Scholar
  21. 21.
    Strom TB, Carpenter CB (1983) Transplantation: Immunogenetic and clinical aspects. Hosp Pract Jan 1983: 135–150Google Scholar
  22. 22.
    Strom TB, Murphy JR, Williams D, Kelley VE (1988) Interleukin-2 toxin: A trojan horse strategy for controlling rejection. Immunol Allergol Clin North Am 8: 69Google Scholar
  23. 23.
    Thomson AW (1990) FK 506 enters the clinic. Immunol Today 11: 35PubMedCrossRefGoogle Scholar
  24. 24.
    Todd PA, Brogden RN (1989) Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs 37: 872Google Scholar
  25. 25.
    Waldman TA (1988) The multichain interleukin-2 receptor: a traget for immunotherapy of patients with adult T cell leukemia, autoimmune disorders and individuals receiving allografts. J Autoimmunity 1: 641CrossRefGoogle Scholar
  26. 26.
    Walter P, Dickneite G, Feifel G, Thies J (1987) Deoxysperagualin induces tolerance in allogeneic kidney transplantation. Transplant Proc 19: 3980PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • Rudolf Peter Wüthrich
    • 1
  1. 1.Department of Medicine, Division of NephrologyUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations